We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

First Gene Found Linked to Heart Attack Risk

By Biotechdaily staff writers
Posted on 18 Feb 2004
Scientists have identified the first gene linked to the common form of heart attack and have found that it confers about a twofold increased risk while also increasing the risk of stroke. The findings were reported in the February 9, 2004, online issue of Nature Genetics.

Researchers from deCode Genetics (Reykjavik, Iceland) identified the at-risk haplotype through the analysis of detailed genotypic data from several thousand patients and unaffected relatives in Iceland participating in the company's cardiovascular disease programs. Analysis of a linkage peak on chromosome 13 with a dense set of single nucleotide polymorphisms (SNPs) revealed a four-SNP haplotype spanning the gene encoding 5-lipoxygenase activating protein, or FLAP (ALOX5AP), which confers about a twofold increased risk of heart attack. By genotyping and comparing the same SNPs in a large group of Icelandic stroke patients with a significantly higher risk of stroke, the same haplotype was also found to correlate with a significantly higher risk of stroke. The researchers also worked with UK doctors analyzing genotypic data from 1,500 British heart attack patients and control and found a similar risk associated with variations in the gene encoding FLAP, but with a different four-SNP haplotype.

Research by the decode team combined with prior studies suggest that upregulation of the gene encoding FLAP may contribute to the inflammation and rupture of atherosclerotic plaque, a common event directly preceding both heart attack and stroke. deCode says its findings suggest that inhibiting the activity of FLAP may thus be an effective means of reducing inflammation and thereby preventing the development of heart attacks and stroke. In fact, deCode has in-licensed a compound, DG031, designed to inhibit FLAP, and clinical trials are being planned.




Related Links:
Decode Genetics

New
Gold Member
Clinical Chemistry Assay
Sorbitol Dehydrogenase (SDH)
New
Gold Member
Aspiration System
VACUSAFE
New
Urine Analyzer
responsĀ® UDS100
New
HIV-1 Molecular Diagnostic Assay
AltoStar HIV RT-PCR Kit 1.5

Latest BioResearch News

Study Identifies Protein Changes Driving Immunotherapy Resistance in Multiple Myeloma
18 Feb 2004  |   BioResearch

Genetic Analysis Identifies BRCA-Linked Risks Across Multiple Cancers
18 Feb 2004  |   BioResearch

Study Identifies Hidden B-Cell Mutations in Autoimmune Disease
18 Feb 2004  |   BioResearch